OPTN/SRTR 2013 Annual Data Report: Liver

Kim, Woojin; Lake, John R.; Smith, Jodi M.; Skeans, M. A.; Schladt, David; Edwards, Erik; Harper, Ann; Wainright, J. L.; Snyder, Jon J.; Israni, Ajay K.; Kasiske, B. L.

doi:10.1111/ajt.13197

Cited by 296 publications

(195 citation statements)

References 0 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…HCV positivity has been observed in 5.6% of all potential donors, and in 18% of potential PHS (public health safety) increased risk donors, who are defined as being "at a higher than average risk for transmitting viruses such as HIV, HCV, and hepatitis B (HBV)" [7,22]. were discarded [5,6,23]. This percentage has dramatically decreased (from 28% in 2010 to 11% in 2015) with the advent of the DAAs, with corresponding increase of HCV-positive liver grafts to HCV-positive recipients [5].…”

Section: Discussionmentioning

confidence: 99%

Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago

et al. 2018

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV)-infected organs are being transplanted in patients with and without HCV in the direct-acting antiviral era. Little is known about patient attitudes towards receiving an HCV-positive organ. Objectives: The aim of this study is to determine transplant candidates’ attitudes towards receiving HCV-positive organs. Methods: Adult solid organ transplant candidates were identified during a clinic visit or during outpatient hemodialysis from May to December 2017. Willing participants completed a survey. Descriptive analysis including mean and median for continuous variables and frequencies for categorical variables were calculated by the appropriate statistical method and compared across willing, unsure, and unwilling patients and between willing and unsure/unwilling patients. Results: Fifty patients were surveyed with median age 54.5 years (range 32–77). Eighty-eight percent were awaiting kidney transplant, and 12% were awaiting other organs. Median waitlist time was 39.8 months (range 1.7–203 months). Most patients (90%) had prior knowledge of HCV, but only 60% knew it was curable. Forty-six percent were willing, 30% were unsure, and 24% were unwilling to receive an HCV-positive organ. Those willing to accept an HCV-positive organ were significantly older, Caucasian, had shorter waitlist times, and had greater physician trust than those that were unsure/unwilling. Similar worries, such as HCV incurability, insurance coverage, fears over the organ not working, and post-transplant death, were expressed in both the willing and unsure/unwilling patients. Conclusions: The availability of HCV-positive organs may expand the donor pool and decrease waitlist times and mortality. These data highlight the need for patient education towards use of these organs.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago

et al. 2018

View full text Add to dashboard Cite

show abstract

“…28 Even regression of cirrhosis was demonstrated in some cases. 29 The improved SVR rates and safety profiles of all oral DAA has led to the treatment of patients with decompensated cirrhosis awaiting LT. 30 Moreover, it has been shown that HCV RNA becomes negative after 2-4 weeks of treatment, and those who are transplanted after becoming HCV RNA negative will be have very low the risk of HCV recurrence after transplantation. 31 This treatment is generally well tolerated and there is no difference in the incidence of hospitalization, sepsis and death between treated and untreated cohorts.…”

Section: Treatment Before Transplantationmentioning

confidence: 99%

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Anand

2017

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…Chronic hepatitis C-associated liver disease accounts for 13-25% of liver transplantations in the ET and UNOS regions [13,36]. The leading indications for liver transplantation are functional liver failure and early HCC in patients with compensated cirrhosis [37].…”

Section: Antiviral Therapy In Hcv-associated Liver Cirrhosis and Hcv mentioning

confidence: 99%

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)

Welker

Zeuzem

2016

Visc Med

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV)- and hepatitis C virus (HCV)-associated liver cirrhosis is a major indication for liver transplantation. This concise review gives an overview about current interferon (IFN)-free treatment options before and after liver transplantation in HBV- or HCV-associated liver disease. Methods: A PubMed database search using the terms hepatitis B, hepatitis C, cirrhosis, and liver transplantation was performed to identify significant clinical studies as well as national and international guidelines. Results: Studies investigating IFN-free treatment in patients with decompensated HBV as well as in HCV-associated cirrhosis are scarce. Hepatic recompensation during antiviral therapy seems more frequent in patients with HBV than in those with HCV-associated cirrhosis. Graft hepatitis B or C is characterized by an accelerated and unfavorable course. Graft infection prophylaxis is safe and efficacious in HBV-related liver transplantation. Eradication of HCV prior to liver transplantation prevents HCV graft infection, and IFN-free treatment of established HCV graft infection is safe and associated with high sustained virologic response rates. Conclusion: Patients with HBV-associated cirrhosis should be treated prior to liver transplantation, and receive a continuing graft infection prophylaxis thereafter. Patients with HCV-associated decompensated cirrhosis may be considered as candidates for antiviral therapy prior to liver transplantation or may be treated subsequently.

show abstract

OPTN/SRTR 2013 Annual Data Report: Liver

Cited by 296 publications

References 0 publications

Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago

Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)

Contact Info

Product

Resources

About